KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Debt: 2017-2024

Historic Total Debt for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $32.5 million.

  • Aquestive Therapeutics' Total Debt rose 15.95% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.2 million, marking a year-over-year increase of 361.09%. This contributed to the annual value of $32.5 million for FY2024, which is 18.15% up from last year.
  • Aquestive Therapeutics' Total Debt amounted to $32.5 million in FY2024, which was up 18.15% from $27.5 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Total Debt peaked at $53.6 million during FY2021, and registered a low of $27.5 million during FY2023.
  • Over the past 3 years, Aquestive Therapeutics' median Total Debt value was $32.5 million (recorded in 2024), while the average stood at $37.4 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Total Debt soared by 45.18% in 2021, and later tumbled by 47.21% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Total Debt (Yearly) stood at $36.9 million in 2020, then soared by 45.18% to $53.6 million in 2021, then fell by 2.67% to $52.1 million in 2022, then plummeted by 47.21% to $27.5 million in 2023, then climbed by 18.15% to $32.5 million in 2024.